Allspring Global Investments Holdings LLC Sells 49,764 Shares of Boston Scientific Corporation $BSX

Allspring Global Investments Holdings LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 2.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,805,476 shares of the medical equipment provider’s stock after selling 49,764 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Boston Scientific were worth $189,178,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. 1248 Management LLC bought a new stake in Boston Scientific during the first quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific during the first quarter worth approximately $27,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific during the second quarter worth approximately $37,000. Finally, Activest Wealth Management increased its stake in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 1.9%

Shares of NYSE BSX opened at $95.41 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market capitalization of $141.38 billion, a price-to-earnings ratio of 56.79, a PEG ratio of 2.30 and a beta of 0.61. The stock has a 50 day moving average price of $101.98 and a 200 day moving average price of $101.87. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Wells Fargo & Company boosted their target price on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average price target of $120.71.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.